Seralutinib (GB002) –
Pulmonary Arterial Hypertension

Condition: Pulmonary Arterial Hypertension
Phase: Phase2
Description: The primary objective for this trial is to determine the effect of GB002 on improving pulmonary hemodynamics in subjects with World Health Organization (WHO) Group 1 PAH who are Functional Class (FC) II and III. The secondary objective for this trial is to determine the effect of GB002 on improving exercise capacity in this population.